Centessa Pharmaceuticals plc (LON:0ACX)

Centessa Pharmaceuticals Statistics

Total Valuation

LON:0ACX has a market cap or net worth of GBP 2.43 billion. The enterprise value is 2.33 billion.

Market Cap	2.43B
Enterprise Value	2.33B

Important Dates

The next estimated earnings date is Wednesday, November 12, 2025.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+27.54%
Shares Change (QoQ)	+0.48%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	85.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	221.90
PB Ratio	9.65
P/TBV Ratio	9.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-13.86
EV / Sales	206.93
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-22.16

Financial Position

The company has a current ratio of 10.12, with a Debt / Equity ratio of 0.34.

Current Ratio	10.12
Quick Ratio	9.93
Debt / Equity	0.34
Debt / EBITDA	n/a
Debt / FCF	-0.82
Interest Coverage	-19.12

Financial Efficiency

Return on equity (ROE) is -72.92% and return on invested capital (ROIC) is -30.88%.

Return on Equity (ROE)	-72.92%
Return on Assets (ROA)	-28.96%
Return on Invested Capital (ROIC)	-30.88%
Return on Capital Employed (ROCE)	-44.64%
Revenue Per Employee	111,719
Profits Per Employee	-1.72M
Employee Count	77
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

In the past 12 months, LON:0ACX has paid 2.80 million in taxes.

Income Tax	2.80M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +49.99% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+49.99%
50-Day Moving Average	20.83
200-Day Moving Average	16.70
Relative Strength Index (RSI)	60.87
Average Volume (20 Days)	302

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.21

Income Statement

In the last 12 months, LON:0ACX had revenue of GBP 10.95 million and -168.15 million in losses. Loss per share was -1.31.

Revenue	10.95M
Gross Profit	10.95M
Operating Income	-150.66M
Pretax Income	-165.35M
Net Income	-168.15M
EBITDA	-150.44M
EBIT	-150.66M
Loss Per Share	-1.31

Balance Sheet

The company has 183.00 million in cash and 86.23 million in debt, giving a net cash position of 96.77 million.

Cash & Cash Equivalents	183.00M
Total Debt	86.23M
Net Cash	96.77M
Net Cash Per Share	n/a
Equity (Book Value)	251.76M
Book Value Per Share	1.88
Working Capital	197.56M

Cash Flow

In the last 12 months, operating cash flow was -105.02 million and capital expenditures -116,784, giving a free cash flow of -105.14 million.

Operating Cash Flow	-105.02M
Capital Expenditures	-116,784
Free Cash Flow	-105.14M
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-1,376.10%
Pretax Margin	-1,510.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0ACX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.54%
Shareholder Yield	-27.54%
Earnings Yield	-6.92%
FCF Yield	-4.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0ACX has an Altman Z-Score of 3.85 and a Piotroski F-Score of 2.

Altman Z-Score	3.85
Piotroski F-Score	2